Cemsidomide (CFT7455) is an orally bioavailable molecular glue degrader under investigation for hematologic malignancies, especially relapsed/refractory multiple myeloma. It acts through cereblon-associated ubiquitin ligase biology to drive degradation of IKZF1/3 and immune-modulatory anti-tumor effects. The candidate remains investigational and is in clinical trial development.
C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.
Cytokinetics launches MYQORZO for obstructive hypertrophic cardiomyopathy following FDA approval, while C4 Therapeutics doses first patient in Phase 2 trial of cemsidomide for relapsed/refractory multiple myeloma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07284758 |
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma |
RECRUITING | PHASE2 |
| NCT07280013 |
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects |
RECRUITING | PHASE1 |
| NCT04756726 |
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma |
ACTIVE_NOT_RECRUITING | PHASE1 |
